New Pathology

Publications

Scientific Publications

Selected peer-reviewed publications authored or co-authored by Dr. Lukas Heukamp in molecular pathology, precision oncology, oncology biomarkers, and genomic diagnostics.

This list is generated from PubMed and refreshed automatically during site builds.

These publications reflect work in molecular pathology, translational oncology, biomarker research, genomic diagnostics, liquid biopsy, and related areas of precision oncology.

  1. Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC.

    Rosnev S, Klein K, Heukamp L, Lenk J, Joosten M, Möbs M, Grob T, Benary M, Vecchione L, Ott CE, Modest DP, Knödler M, Keller U, Frost N, Keilholz U, Kiewe P, Rieke DT

    The oncologist . 2026 .

    PMID: 42015375

  2. Characterization of synaptopodin in striated and smooth muscles: isoform spectrum, expression patterns, localization and protein interactions.

    Lohanadan K, Assent M, Linnemann A, Qu C, Schänzer A, Heukamp L, Milting H, Kirfel G, Miner JH, Fürst DO, van der Ven PFM

    Experimental cell research . 2026 .

    PMID: 41941933

  3. Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

    Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W

    Nature medicine . 2025 .

    PMID: 41266687

  4. Detection of ESR1 Mutations in Tissue and Liquid Biopsy with Novel Next-Generation Sequencing and Digital Droplet PCR Assays: Insights from Multi-Center Real Life Data of Almost 6000 Patients.

    Borkar S, Markus F, Oetting A, Schmidt S, Vössing C, Horst D, Möbs M, Braicu EI, Griesinger F, Horling K, Tiemann K, Heukamp LC, Willing EM, Vollbrecht C

    Cancers . 2025 .

    PMID: 40282442

  5. Intergroup-statement: statement of the german ovarian cancer commission, the North-Eastern German Society of gynecological Oncology (NOGGO), AGO Austria and AGO Swiss regarding the use of homologous repair deficiency (HRD) assays in advanced ovarian cancer.

    Chinczewski L, Harter P, Heukamp L, Mayr D, Grimm C, Heinzelmann-Schwarz V, Wimberger P, Mahner S, Braicu IE, Schmitt W, Denkert C, Sehouli J

    Archives of gynecology and obstetrics . 2025 .

    PMID: 40069521

  6. Targeting KDM1A in Neuroblastoma with NCL-1 Induces a Less Aggressive Phenotype and Suppresses Angiogenesis.

    Sprüssel A, Suzuki T, Miyata N, Astrahantseff K, Szymansky A, Toedling J, Thole-Kliesch TM, Ballagee A, Lodrini M, Künkele A, Truss M, Heukamp LC, Mathia S, Hertwig F, Rosenberger C, Eggert A, Deubzer HE, Schulte JH

    Journal of clinical medicine . 2024 .

    PMID: 39458030

  7. Intracranial response to capmatinib after progression on crizotinib in a patient with MET exon 14 skipping non-small cell lung cancer-a case report.

    Jóri B, Bundschuh O, Falk M, Heukamp LC, Kluge A, Tiemann M, Willborn KC, Woitzik J, Griesinger F

    Translational lung cancer research . 2024 .

    PMID: 39118880

  8. Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy.

    Wagner JN, Roeper J, Heukamp L, Falk M, Willborn K, Griesinger F

    Biomedicines . 2024 .

    PMID: 38540301

  9. High Concordance of Different Assays in the Determination of Homologous Recombination Deficiency-Associated Genomic Instability in Ovarian Cancer.

    Pfarr N, von Schwarzenberg K, Zocholl D, Merkelbach-Bruse S, Siemanowski J, Mayr EM, Herold S, Kleo K, Heukamp LC, Willing EM, Menzel M, Lehmann U, Bartels S, Chakraborty S, Baretton G, Demes MC, Döring C, Kazdal D, Budczies J, Rad R, Wild P, Christinat Y, McKee T, Schirmacher P, Horst D, Büttner R, Stenzinger A, Sehouli J, Vollbrecht C, Hummel M, Braicu EI, Weichert W, German HRD assay Harmonization Consortium

    JCO precision oncology . 2024 .

    PMID: 38513168

  10. Synaptopodin-2 Isoforms Have Specific Binding Partners and Display Distinct, Muscle Cell Type-Specific Expression Patterns.

    Lohanadan K, Assent M, Linnemann A, Schuld J, Heukamp LC, Krause K, Vorgerd M, Reimann J, Schänzer A, Kirfel G, Fürst DO, Van der Ven PFM

    Cells . 2023 .

    PMID: 38201288

  11. The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations.

    Jóri B, Vössing C, Pirngruber J, Willing EM, Arndt K, Falk M, Tiemann M, Heukamp LC, Hoffknecht P

    Current oncology (Toronto, Ont.) . 2023 .

    PMID: 37887535

  12. Development of the NOGGO GIS v1 Assay, a Comprehensive Hybrid-Capture-Based NGS Assay for Therapeutic Stratification of Homologous Repair Deficiency Driven Tumors and Clinical Validation.

    Willing EM, Vollbrecht C, Vössing C, Weist P, Schallenberg S, Herbst JM, Schatz S, Jóri B, Bataillon G, Harter P, Salutari V, Martin AG, Vergote I, Colombo N, Roeper J, Berg T, Berger R, Kah B, Noettrup TJ, Falk M, Arndt K, Polten A, Ray-Coquard I, Selzam F, Pirngruber J, Schmidt S, Hummel M, Tiemann M, Horst D, Sehouli J, Pujade-Lauraine E, Tiemann K, Braicu EI, Heukamp LC

    Cancers . 2023 .

    PMID: 37444554

  13. Response to (K)RAS(G12C) and EGFR Inhibition in a Patient With NRAS(G12C)-Mutated Rectal Cancer.

    Möhrmann L, Cuberi A, Brückmann S, Stasik S, Heukamp LC, Bornhäuser M, Glimm H, Folprecht G

    JCO precision oncology . 2023 .

    PMID: 37262393

  14. Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy.

    Jóri B, Falk M, Hövel I, Weist P, Tiemann M, Heukamp LC, Griesinger F

    Current oncology (Toronto, Ont.) . 2022 .

    PMID: 36135089

  15. The ADP-Ribosylation Factor 4d Restricts Regulatory T-Cell Induction via Control of IL-2 Availability.

    Geers B, Hagenstein J, Endig J, Ulrich H, Fleig L, Sprezyna P, Mikulec J, Heukamp L, Tiegs G, Diehl L

    Cells . 2022 .

    PMID: 36078047

  16. Cell-free tumor DNA, CA125 and HE4 for the objective assessment of tumor burden in patients with advanced high-grade serous ovarian cancer.

    Heitz F, Lakis S, Harter P, Heikaus S, Sehouli J, Talwar J, Menon R, Ataseven B, Bertrand M, Schneider S, Mariotti E, Bommert M, Müller JN, Prader S, Leenders F, Hengsbach A, Gloeckner C, Braicu EI, Heukamp LC, du Bois A, Heuckmann JM

    PloS one . 2022 .

    PMID: 35130283

  17. TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib.

    Roeper J, Christopoulos P, Falk M, Heukamp LC, Tiemann M, Stenzinger A, Thomas M, Griesinger F

    Translational lung cancer research . 2022 .

    PMID: 35242623

  18. Smad7 Deficiency in Myeloid Cells Does Not Affect Liver Injury, Inflammation or Fibrosis after Chronic CCl(4) Exposure in Mice.

    Unrau L, Endig J, Goltz D, Sprezyna P, Ulrich H, Hagenstein J, Geers B, Kaftan K, Heukamp LC, Tiegs G, Diehl L

    International journal of molecular sciences . 2021 .

    PMID: 34769006

  19. Immune related endonucleases and GTPases are not associated with tumor response in patients with advanced non-small cell lung cancer treated with checkpoint inhibitors.

    Ramdani HO, Falk M, Heukamp LC, Schatz S, Tiemann M, Wesseler C, Diehl L, Schuuring E, Groen HJM, Griesinger F

    Pathology, research and practice . 2021 .

    PMID: 34673351

  20. Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel Sequencing.

    Szymansky A, Kruetzfeldt LM, Heukamp LC, Hertwig F, Theissen J, Deubzer HE, Willing EM, Menon R, Fuchs S, Thole T, Schulte S, Schmelz K, Künkele A, Lang P, Fuchs J, Eggert A, Eckert C, Fischer M, Henssen AG, Rodriguez-Fos E, Schulte JH

    Journal of personalized medicine . 2021 .

    PMID: 34442335

  21. Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy.

    Jóri B, Schatz S, Kaller L, Kah B, Roeper J, Ramdani HO, Diehl L, Hoffknecht P, Grohé C, Griesinger F, Tiemann M, Heukamp LC, Falk M

    Cancers . 2021 .

    PMID: 34201252

  22. Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184].

    Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn MO, Maintz C, Bernhardt C, Losem C, Stenzinger A, Heukamp LC, Büttner R, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Heilmann M, Sadjadian P, Gleiber W, Grah C, Waller CF, Reck M, Rittmeyer A, Christopoulos P, Sebastian M, Thomas M, CRISP Registry Group

    Lung cancer (Amsterdam, Netherlands) . 2021 .

    PMID: 34049721

  23. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.

    Wiesweg M, Preuß C, Roeper J, Metzenmacher M, Eberhardt W, Stropiep U, Wedeken K, Reis H, Herold T, Darwiche K, Aigner C, Stuschke M, Schildhaus HU, Schmid KW, Falk M, Heukamp L, Tiemann M, Griesinger F, Schuler M

    European journal of cancer (Oxford, England : 1990) . 2021 .

    PMID: 33872981

  24. Notch1 Deficiency Induces Tumor Cell Accumulation Inside the Bronchiolar Lumen and Increases TAZ Expression in an Autochthonous Kras (LSL-G12V) Driven Lung Cancer Mouse Model.

    Meder L, Florin A, Ozretić L, Nill M, Koker M, Meemboor S, Radtke F, Diehl L, Ullrich RT, Odenthal M, Büttner R, Heukamp LC

    Pathology oncology research : POR . 2021 .

    PMID: 34257546

  25. NOX2 Deficiency Permits Sustained Survival of S. aureus in Macrophages and Contributes to Severity of Infection.

    Tosetti B, Ward B, Grumme D, Herb M, Schramm M, Utermöhlen O, Heukamp LC, Krönke M, Krut O

    Frontiers in immunology . 2021 .

    PMID: 33868252

  26. Inflammatory myofibroblastic tumour of the central airways: treatment and molecular analysis.

    Iyer A, Radonic T, Heukamp LC, Thunnissen E, Daniels JMA

    ERJ open research . 2021 .

    PMID: 33778057

  27. KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).

    Sebastian M, Eberhardt WEE, Hoffknecht P, Metzenmacher M, Wehler T, Kokowski K, Alt J, Schütte W, Büttner R, Heukamp LC, Stenzinger A, Jänicke M, Fleitz A, Zacharias S, Dille S, Hipper A, Sandberg M, Weichert W, Groschek M, von der Heyde E, Rauh J, Dechow T, Thomas M, Griesinger F, CRISP Registry Group

    Lung cancer (Amsterdam, Netherlands) . 2021 .

    PMID: 33611226

  28. Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program.

    Frost N, Christopoulos P, Kauffmann-Guerrero D, Stratmann J, Riedel R, Schaefer M, Alt J, Gütz S, Christoph DC, Laack E, Faehling M, Fischer R, Fenchel K, Haen S, Heukamp L, Schulz C, Griesinger F

    Therapeutic advances in medical oncology . 2021 .

    PMID: 33613692

  29. [Diagnosis and therapy of tumors with NTRK gene fusion].

    Stenzinger A, van Tilburg CM, Tabatabai G, Länger F, Graf N, Griesinger F, Heukamp LC, Hummel M, Klingebiel T, Hettmer S, Vokuhl C, Merkelbach-Bruse S, Overkamp F, Reichardt P, Scheer M, Weichert W, Westphalen CB, Bokemeyer C, Ivanyi P, Loges S, Schirmacher P, Wörmann B, Bielack S, Seufferlein TTW

    Der Pathologe . 2021 .

    PMID: 33258061

  30. ALK alterations in salivary gland carcinomas.

    Majewska H, Gorczyński A, Czapiewski P, Menon R, Mueller J, Lakis S, Heuckmann JM, Laco J, Gupta R, Andreasen S, Stodulski D, Iliszko M, Dziadziuszko R, Jassem J, Heukamp LC, Biernat W

    Virchows Archiv : an international journal of pathology . 2021 .

    PMID: 33237469

  31. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).

    Griesinger F, Eberhardt W, Nusch A, Reiser M, Zahn MO, Maintz C, Bernhardt C, Losem C, Stenzinger A, Heukamp LC, Büttner R, Marschner N, Jänicke M, Fleitz A, Spring L, Sahlmann J, Karatas A, Hipper A, Weichert W, Heilmann M, Sadjadian P, Gleiber W, Grah C, Waller CF, Reck M, Rittmeyer A, Christopoulos P, Sebastian M, Thomas M, CRISP Registry Group

    Lung cancer (Amsterdam, Netherlands) . 2021 .

    PMID: 33358484

  32. Risk stratification of EGFR(+) lung cancer diagnosed with panel-based next-generation sequencing.

    Christopoulos P, Kirchner M, Roeper J, Saalfeld F, Janning M, Bozorgmehr F, Magios N, Kazdal D, Volckmar AL, Brückner LM, Bochtler T, Kriegsmann M, Endris V, Penzel R, Kriegsmann K, Eichhorn M, Herth FJF, Heussel CP, El Shafie RA, Schneider MA, Muley T, Meister M, Faehling M, Fischer JR, Heukamp L, Schirmacher P, Bischoff H, Wermke M, Loges S, Griesinger F, Stenzinger A, Thomas M

    Lung cancer (Amsterdam, Netherlands) . 2020 .

    PMID: 32871455

  33. Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer.

    Schatz S, Falk M, Jóri B, Ramdani HO, Schmidt S, Willing EM, Menon R, Groen HJM, Diehl L, Kröger M, Wesseler C, Griesinger F, Hoffknecht P, Tiemann M, Heukamp LC

    Cancers . 2020 .

    PMID: 32599951

  34. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.

    Wagener-Ryczek S, Heydt C, Süptitz J, Michels S, Falk M, Alidousty C, Fassunke J, Ihle MA, Tiemann M, Heukamp L, Wolf J, Büttner R, Merkelbach-Bruse S

    BMC cancer . 2020 .

    PMID: 32397977

  35. Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC.

    Volz C, Breid S, Selenz C, Zaplatina A, Golfmann K, Meder L, Dietlein F, Borchmann S, Chatterjee S, Siobal M, Schöttle J, Florin A, Koker M, Nill M, Ozretić L, Uhlenbrock N, Smith S, Büttner R, Miao H, Wang B, Reinhardt HC, Rauh D, Hallek M, Acker-Palmer A, Heukamp LC, Ullrich RT

    Cell reports . 2020 .

    PMID: 32348765

  36. Pioglitazone-Mediated Peroxisome Proliferator-Activated Receptor γ Activation Aggravates Murine Immune-Mediated Hepatitis.

    Schulte R, Wohlleber D, Unrau L, Geers B, Metzger C, Erhardt A, Tiegs G, van Rooijen N, Heukamp LC, Klotz L, Knolle PA, Diehl L

    International journal of molecular sciences . 2020 .

    PMID: 32260486

  37. Integrated clinicomolecular characterization identifies RAS activation and CDKN2A deletion as independent adverse prognostic factors in cancer of unknown primary.

    Bochtler T, Reiling A, Endris V, Hielscher T, Volckmar AL, Neumann O, Kirchner M, Budczies J, Heukamp LC, Leichsenring J, Allgäuer M, Kazdal D, Löffler H, Weichert W, Schirmacher P, Stenzinger A, Krämer A

    International journal of cancer . 2020 .

    PMID: 31970771

  38. TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC.

    Roeper J, Falk M, Chalaris-Rißmann A, Lueers AC, Ramdani H, Wedeken K, Stropiep U, Diehl L, Tiemann M, Heukamp LC, Otto-Sobotka F, Griesinger F

    Oncotarget . 2020 .

    PMID: 32076486

  39. Acute Liver Injury after CCl(4) Administration is Independent of Smad7 Expression in Myeloid Cells.

    Endig J, Unrau L, Sprezyna P, Rading S, Karsak M, Goltz D, Heukamp LC, Tiegs G, Diehl L

    International journal of molecular sciences . 2019 .

    PMID: 31698731

  40. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.

    Thunnissen E, Lissenberg-Witte BI, van den Heuvel MM, Monkhorst K, Skov BG, Sørensen JB, Mellemgaard A, Dingemans AMC, Speel EJM, de Langen AJ, Hashemi SMS, Bahce I, van der Drift MA, Looijen-Salamon MG, Gosney J, Postmus PE, Samii SMS, Duplaquet F, Weynand B, Durando X, Penault-Llorca F, Finn S, Grady AO, Oz B, Akyurek N, Buettner R, Wolf J, Bubendorf L, Duin S, Marondel I, Heukamp LC, Timens W, Schuuring EMD, Pauwels P, Smit EF

    Lung cancer (Amsterdam, Netherlands) . 2019 .

    PMID: 31630043

  41. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.

    Michels S, Massutí B, Schildhaus HU, Franklin J, Sebastian M, Felip E, Grohé C, Rodriguez-Abreu D, Abdulla DSY, Bischoff H, Brandts C, Carcereny E, Corral J, Dingemans AC, Pereira E, Fassunke J, Fischer RN, Gardizi M, Heukamp L, Insa A, Kron A, Menon R, Persigehl T, Reck M, Riedel R, Rothschild SI, Scheel AH, Scheffler M, Schmalz P, Smit EF, Limburg M, Provencio M, Karachaliou N, Merkelbach-Bruse S, Hellmich M, Nogova L, Büttner R, Rosell R, Wolf J

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer . 2019 .

    PMID: 30978502

  42. Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer.

    Michels S, Heydt C, van Veggel B, Deschler-Baier B, Pardo N, Monkhorst K, Rüsseler V, Stratmann J, Griesinger F, Steinhauser S, Kostenko A, Diebold J, Fassunke J, Fischer R, Engel-Riedel W, Gautschi O, Geissinger E, Haneder S, Ihle MA, Kopp HG, de Langen AJ, Martinez-Marti A, Nogova L, Persigehl T, Plenker D, Puesken M, Rodermann E, Rosenwald A, Scheel AH, Scheffler M, Spengler W, Seggewiss-Bernhardt R, Brägelmann J, Sebastian M, Vrugt B, Hellmich M, Sos ML, Heukamp LC, Felip E, Merkelbach-Bruse S, Smit EF, Büttner R, Wolf J

    JCO precision oncology . 2019 .

    PMID: 32914023

  43. The small molecule Bcl-2/Mcl-1 inhibitor TW-37 shows single-agent cytotoxicity in neuroblastoma cell lines.

    Klenke S, Akdeli N, Stelmach P, Heukamp L, Schulte JH, Bachmann HS

    BMC cancer . 2019 .

    PMID: 30885150

  44. The PDL1-inducible GTPase Arl4d controls T effector function by limiting IL-2 production.

    Tolksdorf F, Mikulec J, Geers B, Endig J, Sprezyna P, Heukamp LC, Knolle PA, Kolanus W, Diehl L

    Scientific reports . 2018 .

    PMID: 30382149

  45. Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC).

    Frank R, Scheffler M, Merkelbach-Bruse S, Ihle MA, Kron A, Rauer M, Ueckeroth F, König K, Michels S, Fischer R, Eisert A, Fassunke J, Heydt C, Serke M, Ko YD, Gerigk U, Geist T, Kaminsky B, Heukamp LC, Clement-Ziza M, Büttner R, Wolf J

    Clinical cancer research : an official journal of the American Association for Cancer Research . 2018 .

    PMID: 29615460

  46. Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica.

    Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A, Bahleda R, Jamme P, Gelli M, Goere D, Lacroix L, Adam J, Heukamp L, Trenta P, Hembrough T, Soria JC, Sternberg C, Ducreux M

    Tumori . 2018 .

    PMID: 29714649

  47. LIN28B enhanced tumorigenesis in an autochthonous KRAS(G12V)-driven lung carcinoma mouse model.

    Meder L, König K, Dietlein F, Macheleidt I, Florin A, Ercanoglu MS, Rommerscheidt-Fuss U, Koker M, Schön G, Odenthal M, Klein F, Büttner R, Schulte JH, Heukamp LC, Ullrich RT

    Oncogene . 2018 .

    PMID: 29503447

  48. Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tübingen, Germany.

    Bailey DL, Pichler BJ, Gückel B, Antoch G, Barthel H, Bhujwalla ZM, Biskup S, Biswal S, Bitzer M, Boellaard R, Braren RF, Brendle C, Brindle K, Chiti A, la Fougère C, Gillies R, Goh V, Goyen M, Hacker M, Heukamp L, Knudsen GM, Krackhardt AM, Law I, Morris JC, Nikolaou K, Nuyts J, Ordonez AA, Pantel K, Quick HH, Riklund K, Sabri O, Sattler B, Troost EGC, Zaiss M, Zender L, Beyer T

    Molecular imaging and biology . 2018 .

    PMID: 28971346

  49. Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.

    Plenker D, Bertrand M, de Langen AJ, Riedel R, Lorenz C, Scheel AH, Müller J, Brägelmann J, Daßler-Plenker J, Kobe C, Persigehl T, Kluge A, Wurdinger T, Schellen P, Hartmann G, Zacherle T, Menon R, Thunnissen E, Büttner R, Griesinger F, Wolf J, Heukamp L, Sos ML, Heuckmann JM

    Clinical cancer research : an official journal of the American Association for Cancer Research . 2018 .

    PMID: 29284707

  50. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.

    Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T, Heukamp LC, Jasani B, Jöhrens K, Kirchner T, Lasitschka F, Petersen I, Reu S, Schildhaus HU, Schirmacher P, Schwamborn K, Sommer U, Stoss O, Tiemann M, Warth A, Weichert W, Wolf J, Büttner R, Rüschoff J

    Histopathology . 2018 .

    PMID: 28851100

  51. Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non-Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy.

    Lakis S, Heukamp LC, Griesinger F

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer . 2017 .

    PMID: 29074212

  52. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.

    Brägelmann J, Dammert MA, Dietlein F, Heuckmann JM, Choidas A, Böhm S, Richters A, Basu D, Tischler V, Lorenz C, Habenberger P, Fang Z, Ortiz-Cuaran S, Leenders F, Eickhoff J, Koch U, Getlik M, Termathe M, Sallouh M, Greff Z, Varga Z, Balke-Want H, French CA, Peifer M, Reinhardt HC, Örfi L, Kéri G, Ansén S, Heukamp LC, Büttner R, Rauh D, Klebl BM, Thomas RK, Sos ML

    Cell reports . 2017 .

    PMID: 28930680

  53. Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens.

    Müller JN, Falk M, Talwar J, Neemann N, Mariotti E, Bertrand M, Zacherle T, Lakis S, Menon R, Gloeckner C, Tiemann M, Heukamp LC, Thomas RK, Griesinger F, Heuckmann JM

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer . 2017 .

    PMID: 28751246

  54. RITA displays anti-tumor activity in medulloblastomas independent of TP53 status.

    Gottlieb A, Althoff K, Grunewald L, Thor T, Odersky A, Schulte M, Deubzer HE, Heukamp L, Eggert A, Schramm A, Schulte JH, Künkele A

    Oncotarget . 2017 .

    PMID: 28427187

  55. ALK(G1269A) mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor.

    Michels SYF, Scheel AH, Wündisch T, Heuckmann JM, Menon R, Puesken M, Kobe C, Pasternack H, Heydt C, Scheffler M, Fischer R, Schultheis AM, Merkelbach-Bruse S, Heukamp L, Büttner R, Wolf J

    NPJ precision oncology . 2017 .

    PMID: 29872693

  56. Correction: Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine.

    Ladang A, Rapino F, Heukamp LC, Tharun L, Shostak K, Hermand D, Delaunay S, Klevernic I, Jiang Z, Jacques N, Jamart D, Migeot V, Florin A, Göktuna S, Malgrange B, Sansom OJ, Nguyen L, Büttner R, Close P, Chariot A

    The Journal of experimental medicine . 2017 .

    PMID: 28283535

  57. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.

    Pajtler KW, Sadowski N, Ackermann S, Althoff K, Schönbeck K, Batzke K, Schäfers S, Odersky A, Heukamp L, Astrahantseff K, Künkele A, Deubzer HE, Schramm A, Sprüssel A, Thor T, Lindner S, Eggert A, Fischer M, Schulte JH

    Oncotarget . 2017 .

    PMID: 28036269

  58. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].

    Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Büttner R

    Der Pathologe . 2016 .

    PMID: 27510417

  59. Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer.

    Delaunay S, Rapino F, Tharun L, Zhou Z, Heukamp L, Termathe M, Shostak K, Klevernic I, Florin A, Desmecht H, Desmet CJ, Nguyen L, Leidel SA, Willis AE, Büttner R, Chariot A, Close P

    The Journal of experimental medicine . 2016 .

    PMID: 27811057

  60. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.

    Latteyer S, Tiedje V, König K, Ting S, Heukamp LC, Meder L, Schmid KW, Führer D, Moeller LC

    Endocrine . 2016 .

    PMID: 27696251

  61. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas.

    Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, Rüschoff J, Schildhaus HU, Schirmacher P, Tiemann M, Warth A, Weichert W, Fischer RN, Wolf J, Buettner R

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc . 2016 .

    PMID: 27389313

  62. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.

    Rosoux A, Pauwels P, Duplaquet F, D'Haene N, Weynand B, Delos M, Menon R, Heukamp LC, Thunnissen E, Ocak S

    Lung cancer (Amsterdam, Netherlands) . 2016 .

    PMID: 27393517

  63. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.

    Ortiz-Cuaran S, Scheffler M, Plenker D, Dahmen L, Scheel AH, Fernandez-Cuesta L, Meder L, Lovly CM, Persigehl T, Merkelbach-Bruse S, Bos M, Michels S, Fischer R, Albus K, König K, Schildhaus HU, Fassunke J, Ihle MA, Pasternack H, Heydt C, Becker C, Altmüller J, Ji H, Müller C, Florin A, Heuckmann JM, Nuernberg P, Ansén S, Heukamp LC, Berg J, Pao W, Peifer M, Buettner R, Wolf J, Thomas RK, Sos ML

    Clinical cancer research : an official journal of the American Association for Cancer Research . 2016 .

    PMID: 27252416

  64. Retraction Notice to: Cytohesins Are Cytoplasmic ErbB Receptor Activators.

    Bill A, Schmitz A, Albertoni B, Song JN, Heukamp LC, Walrafen D, Thorwirth F, Verveer PJ, Zimmer S, Meffert L, Schreiber A, Chatterjee S, Thomas RK, Ullrich RT, Lang T, Famulok M

    Cell . 2016 .

    PMID: 27203114

  65. A Novel EGFR(C797) Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay.

    Menon R, Müller J, Schneider P, Lakis S, Thress K, Wolf J, Heukamp L, Heuckmann JM, Griesinger F

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer . 2016 .

    PMID: 27086175

  66. The Prosurvival IKK-Related Kinase IKKε Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine.

    Göktuna SI, Shostak K, Chau TL, Heukamp LC, Hennuy B, Duong HQ, Ladang A, Close P, Klevernic I, Olivier F, Florin A, Ehx G, Baron F, Vandereyken M, Rahmouni S, Vereecke L, van Loo G, Büttner R, Greten FR, Chariot A

    Cancer research . 2016 .

    PMID: 26980769

  67. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.

    Michels S, Scheel AH, Scheffler M, Schultheis AM, Gautschi O, Aebersold F, Diebold J, Pall G, Rothschild S, Bubendorf L, Hartmann W, Heukamp L, Schildhaus HU, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Fischer R, Nogovà L, Mattonet C, Hein R, Adams A, Gerigk U, Schulte W, Lüders H, Grohé C, Graeven U, Müller-Naendrup C, Draube A, Kambartel KO, Krüger S, Schulze-Olden S, Serke M, Engel-Riedel W, Kaminsky B, Randerath W, Merkelbach-Bruse S, Büttner R, Wolf J

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer . 2016 .

    PMID: 26762747

  68. Mutational analysis of pulmonary tumours with neuroendocrine features using targeted massive parallel sequencing: a comparison of a neglected tumour group.

    Vollbrecht C, Werner R, Walter RF, Christoph DC, Heukamp LC, Peifer M, Hirsch B, Burbat L, Mairinger T, Schmid KW, Wohlschlaeger J, Mairinger FD

    British journal of cancer . 2015 .

    PMID: 26645239

  69. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.

    Henssen A, Althoff K, Odersky A, Beckers A, Koche R, Speleman F, Schäfers S, Bell E, Nortmeyer M, Westermann F, De Preter K, Florin A, Heukamp L, Spruessel A, Astrahanseff K, Lindner S, Sadowski N, Schramm A, Astorgues-Xerri L, Riveiro ME, Eggert A, Cvitkovic E, Schulte JH

    Clinical cancer research : an official journal of the American Association for Cancer Research . 2016 .

    PMID: 26631615

  70. Successful AZD9291 Therapy Based on Circulating T790M.

    Gautschi O, Aebi S, Heukamp LC

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer . 2015 .

    PMID: 26709490

  71. Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer.

    Schöttle J, Chatterjee S, Volz C, Siobal M, Florin A, Rokitta D, Hinze Y, Dietlein F, Plenker D, König K, Albus K, Heuckmann JM, Rauh D, Franz T, Neumaier B, Fuhr U, Heukamp LC, Ullrich RT

    Oncotarget . 2015 .

    PMID: 26540572

  72. Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients.

    Majores M, Schindler A, Fuchs A, Stein J, Heukamp L, Altevogt P, Kristiansen G

    BMC clinical pathology . 2015 .

    PMID: 26578846

  73. Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases.

    Meder L, König K, Fassunke J, Ozretić L, Wolf J, Merkelbach-Bruse S, Heukamp LC, Buettner R

    Experimental and molecular pathology . 2015 .

    PMID: 26546837

  74. Elp3 drives Wnt-dependent tumor initiation and regeneration in the intestine.

    Ladang A, Rapino F, Heukamp LC, Tharun L, Shostak K, Hermand D, Delaunay S, Klevernic I, Jiang Z, Jacques N, Jamart D, Migeot V, Florin A, Göktuna S, Malgrange B, Sansom OJ, Nguyen L, Büttner R, Close P, Chariot A

    The Journal of experimental medicine . 2015 .

    PMID: 26527802

  75. Endogenous Il10 alleviates the systemic antiviral cellular immune response and T cell-mediated immunopathology in select organs of acutely LCMV-infected mice.

    Jakobshagen K, Ward B, Baschuk N, Huss S, Brunn A, Malecki M, Fiolka M, Rappl G, Corogeanu D, Karow U, Schiller P, Abken H, Heukamp LC, Deckert M, Krönke M, Utermöhlen O

    The American journal of pathology . 2015 .

    PMID: 26506472

  76. [Cytological material for molecular pathology].

    Heukamp LC, Bubendorf L

    Der Pathologe . 2015 .

    PMID: 26483251

  77. Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy.

    Gautschi O, Stadelmann C, Aebersold-Keller F, König K, Büttner R, Heukamp LC, Betticher D, Baumann C, Buser K, Calderoni A, Casty A, DʼAddario G, Irlé C, Mamot C, Morant R, Trojan A, Pellicioli E, Jehle-Schwertfeger S, Aebi S, Diebold J

    Oncology research and treatment . 2015 .

    PMID: 26599269

  78. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.

    Meder L, König K, Ozretić L, Schultheis AM, Ueckeroth F, Ade CP, Albus K, Boehm D, Rommerscheidt-Fuss U, Florin A, Buhl T, Hartmann W, Wolf J, Merkelbach-Bruse S, Eilers M, Perner S, Heukamp LC, Buettner R

    International journal of cancer . 2016 .

    PMID: 26340530

  79. Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.

    Grünewald I, Vollbrecht C, Meinrath J, Meyer MF, Heukamp LC, Drebber U, Quaas A, Beutner D, Hüttenbrink KB, Wardelmann E, Hartmann W, Büttner R, Odenthal M, Stenner M

    Oncotarget . 2015 .

    PMID: 26053092

  80. Comprehensive genomic profiles of small cell lung cancer.

    George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK

    Nature . 2015 .

    PMID: 26168399

  81. Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.

    König K, Peifer M, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Stamm K, Ueckeroth F, Vollbrecht C, Bos M, Gardizi M, Scheffler M, Nogova L, Leenders F, Albus K, Meder L, Becker K, Florin A, Rommerscheidt-Fuss U, Altmüller J, Kloth M, Nürnberg P, Henkel T, Bikár SE, Sos ML, Geese WJ, Strauss L, Ko YD, Gerigk U, Odenthal M, Zander T, Wolf J, Merkelbach-Bruse S, Buettner R, Heukamp LC

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer . 2015 .

    PMID: 26102443

  82. Mutational dynamics between primary and relapse neuroblastomas.

    Schramm A, Köster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, Stephan H, Schröder C, Heukamp L, Engesser A, Kahlert Y, Theissen J, Hero B, Roels F, Altmüller J, Nürnberg P, Astrahantseff K, Gloeckner C, De Preter K, Plass C, Lee S, Lode HN, Henrich KO, Gartlgruber M, Speleman F, Schmezer P, Westermann F, Rahmann S, Fischer M, Eggert A, Schulte JH

    Nature genetics . 2015 .

    PMID: 26121086

  83. Comprehensive Analysis of Disease-Related Genes in Chronic Lymphocytic Leukemia by Multiplex PCR-Based Next Generation Sequencing.

    Vollbrecht C, Mairinger FD, Koitzsch U, Peifer M, Koenig K, Heukamp LC, Crispatzu G, Wilden L, Kreuzer KA, Hallek M, Odenthal M, Herling CD, Buettner R

    PloS one . 2015 .

    PMID: 26053404

  84. Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

    Scheffler M, Merkelbach-Bruse S, Bos M, Fassunke J, Gardizi M, Michels S, Groneck L, Schultheis AM, Malchers F, Leenders F, Kobe C, König K, Heukamp LC, Sos ML, Thomas RK, Büttner R, Wolf J

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer . 2015 .

    PMID: 26001148

  85. ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability.

    Scheffler M, Schultheis A, Teixido C, Michels S, Morales-Espinosa D, Viteri S, Hartmann W, Merkelbach-Bruse S, Fischer R, Schildhaus HU, Fassunke J, Sebastian M, Serke M, Kaminsky B, Randerath W, Gerigk U, Ko YD, Krüger S, Schnell R, Rothe A, Kropf-Sanchen C, Heukamp L, Rosell R, Büttner R, Wolf J

    Oncotarget . 2015 .

    PMID: 25868855

  86. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.

    Kloth M, Ruesseler V, Engel C, Koenig K, Peifer M, Mariotti E, Kuenstlinger H, Florin A, Rommerscheidt-Fuss U, Koitzsch U, Wodtke C, Ueckeroth F, Holzapfel S, Aretz S, Propping P, Loeffler M, Merkelbach-Bruse S, Odenthal M, Friedrichs N, Heukamp LC, Zander T, Buettner R

    Gut . 2016 .

    PMID: 26001389

  87. PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.

    Scheffler M, Bos M, Gardizi M, König K, Michels S, Fassunke J, Heydt C, Künstlinger H, Ihle M, Ueckeroth F, Albus K, Serke M, Gerigk U, Schulte W, Töpelt K, Nogova L, Zander T, Engel-Riedel W, Stoelben E, Ko YD, Randerath W, Kaminsky B, Panse J, Becker C, Hellmich M, Merkelbach-Bruse S, Heukamp LC, Büttner R, Wolf J

    Oncotarget . 2015 .

    PMID: 25473901

  88. MiR-34a deficiency accelerates medulloblastoma formation in vivo.

    Thor T, Künkele A, Pajtler KW, Wefers AK, Stephan H, Mestdagh P, Heukamp L, Hartmann W, Vandesompele J, Sadowski N, Becker L, Garrett L, Hölter SM, Horsch M, Calzada-Wack J, Klein-Rodewald T, Racz I, Zimmer A, Beckers J, Neff F, Klopstock T, De Antonellis P, Zollo M, Wurst W, Fuchs H, Gailus-Durner V, Schüller U, de Angelis MH, Eggert A, Schramm A, Schulte JH

    International journal of cancer . 2015 .

    PMID: 25348795

  89. Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell Lymphoma.

    Theurich S, Schlaak M, Steguweit H, Heukamp LC, Wennhold K, Kurschat P, Rabenhorst A, Hartmann K, Schlösser H, Shimabukuro-Vornhagen A, Holtick U, Hallek M, Stadler R, von Bergwelt-Baildon M

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology . 2016 .

    PMID: 25348001

  90. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.

    Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprüssel A, Lindner S, De Preter K, Florin A, Heukamp LC, Klein-Hitpass L, Astrahantseff K, Kumps C, Speleman F, Eggert A, Westermann F, Schramm A, Schulte JH

    Oncogene . 2015 .

    PMID: 25174395

  91. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer.

    Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M, Bos M, Wolf J, Gardizi M, Wright GM, Solomon B, Russell PA, Rogers TM, Suehara Y, Red-Brewer M, Tieu R, de Stanchina E, Wang Q, Zhao Z, Johnson DH, Horn L, Wong KK, Thomas RK, Ladanyi M, Pao W

    Nature medicine . 2014 .

    PMID: 25173427

  92. Comparison of pre-analytical FFPE sample preparation methods and their impact on massively parallel sequencing in routine diagnostics.

    Heydt C, Fassunke J, Künstlinger H, Ihle MA, König K, Heukamp LC, Schildhaus HU, Odenthal M, Büttner R, Merkelbach-Bruse S

    PloS one . 2014 .

    PMID: 25105902

  93. The LIM-only protein FHL2 reduces vascular lesion formation involving inhibition of proliferation and migration of smooth muscle cells.

    Kurakula K, Vos M, Otermin Rubio I, Marinković G, Buettner R, Heukamp LC, Stap J, de Waard V, van Tiel CM, de Vries CJ

    PloS one . 2014 .

    PMID: 24736599

  94. Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.

    Chatterjee S, Wieczorek C, Schöttle J, Siobal M, Hinze Y, Franz T, Florin A, Adamczak J, Heukamp LC, Neumaier B, Ullrich RT

    Cancer research . 2014 .

    PMID: 24675359

  95. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.

    Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretić L, Seidal D, Zander T, Leenders F, George J, Müller C, Dahmen I, Pinther B, Bosco G, Konrad K, Altmüller J, Nürnberg P, Achter V, Lang U, Schneider PM, Bogus M, Soltermann A, Brustugun OT, Helland Å, Solberg S, Lund-Iversen M, Ansén S, Stoelben E, Wright GM, Russell P, Wainer Z, Solomon B, Field JK, Hyde R, Davies MP, Heukamp LC, Petersen I, Perner S, Lovly C, Cappuzzo F, Travis WD, Wolf J, Vingron M, Brambilla E, Haas SA, Buettner R, Thomas RK

    Nature communications . 2014 .

    PMID: 24670920

  96. Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma.

    Schütte U, Bisht S, Heukamp LC, Kebschull M, Florin A, Haarmann J, Hoffmann P, Bendas G, Buettner R, Brossart P, Feldmann G

    Translational oncology . 2014 .

    PMID: 24913676

  97. Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.

    Fuchs A, König K, Heukamp LC, Fassunke J, Kirfel J, Huss S, Becker AJ, Büttner R, Majores M

    Diagnostic pathology . 2014 .

    PMID: 24593867

  98. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC.

    Dietlein F, Thelen L, Jokic M, Jachimowicz RD, Ivan L, Knittel G, Leeser U, van Oers J, Edelmann W, Heukamp LC, Reinhardt HC

    Cancer discovery . 2014 .

    PMID: 24556366

  99. CD74-NRG1 fusions in lung adenocarcinoma.

    Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, Ortiz-Cuaran S, Peifer M, Bos M, Daßler J, Malchers F, Schöttle J, Vogel W, Dahmen I, Koker M, Ullrich RT, Wright GM, Russell PA, Wainer Z, Solomon B, Brambilla E, Nagy-Mignotte H, Moro-Sibilot D, Brambilla CG, Lantuejoul S, Altmüller J, Becker C, Nürnberg P, Heuckmann JM, Stoelben E, Petersen I, Clement JH, Sänger J, Muscarella LA, la Torre A, Fazio VM, Lahortiga I, Perera T, Ogata S, Parade M, Brehmer D, Vingron M, Heukamp LC, Buettner R, Zander T, Wolf J, Perner S, Ansén S, Haas SA, Yatabe Y, Thomas RK

    Cancer discovery . 2014 .

    PMID: 24469108

  100. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.

    Rothe A, Jachimowicz RD, Borchmann S, Madlener M, Keßler J, Reiners KS, Sauer M, Hansen HP, Ullrich RT, Chatterjee S, Borchmann P, Yazaki P, Koslowsky TC, Engert A, Heukamp LC, Hallek M, von Strandmann EP

    International journal of cancer . 2014 .

    PMID: 24242212

View full results on PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Heukamp+L%5BAuthor%5D+OR+Heukamp+LC%5BAuthor%5D

Publications are automatically imported from PubMed using this filter and may contain mismatches.